NCT07421180

Maternal Serum Adropin in Placenta Accreta Spectrum

Maternal Serum Adropin as a Potential Biomarker for Placenta Accreta Spectrum

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 84 (actual)
• Sponsor: Adana City Training and Research Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Methods: This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.

Conditions

• Placenta Accreta Spectrum
• Placenta Previa

Timeline

• Start date: 2024-05-15
• Primary completion: 2025-04-01
• Completion: 2025-04-01
• First posted: 2026-02-19
• Last updated: 2026-02-20

Locations

1 site across 1 country: Turkey (Türkiye)